Glenmark Pharmaceuticals submits supplemental application for Lamotrigine
Glenmark Pharmaceuticals has submitted a supplemental application for Lamotrigine under ANDA090169, currently under standard review.
Company
Pharmaceutical intelligence for Glenmark Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.